Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
PHASE2CompletedINTERVENTIONAL
Enrollment
37
Participants
Timeline
Start Date
August 31, 2005
Primary Completion Date
February 28, 2007
Study Completion Date
May 31, 2008
Conditions
Esophageal Cancer
Interventions
DRUG
bortezomib
DRUG
carboplatin
DRUG
paclitaxel
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
Alliance for Clinical Trials in Oncology
OTHER
NCT00107341 - Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction | Biotech Hunter | Biotech Hunter